MYT1L Human shRNA Plasmid Kit (Locus ID 23040)

Specifications

Product Data
Product Name	MYT1L Human shRNA Plasmid Kit (Locus ID 23040)
Locus ID	23040
UniProt ID	Q9UL68
Synonyms	MRD39; myT1-L; NZF1; ZC2H2C2; ZC2HC4B
Vector	pGFP-C-shLenti
Format	Lentiviral plasmids
Kit Components	MYT1L - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 23040). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq	NM_001303052, NM_001329844, NM_001329845, NM_001329846, NM_001329847, NM_001329848, NM_001329849, NM_001329851, NM_001329852, NM_015025, NM_015025.1, NM_015025.2, NM_015025.3, NM_001303052.1, BC031690, BC042833, BC043230, BC071612, BC109113, BC137272, BC137273, BC150281, BM715930, NM_001303052.2, NM_015025.4
Summary	This gene encodes a member of the zinc finger superfamily of transcription factors whose expression, thus far, has been found only in neuronal tissues. The encoded protein belongs to a novel class of cystein-cystein-histidine-cystein zinc finger proteins that function in the developing mammalian central nervous system. Forced expression of this gene in combination with the basic helix-loop-helix transcription factor NeuroD1 and the transcription factors POU class 3 homeobox 2 and achaete-scute family basic helix-loop-helix transcription factor 1 can convert fetal and postnatal human fibroblasts into induced neuronal cells, which are able to generate action potentials. Mutations in this gene have been associated with an autosomal dominant form of cognitive disability and with autism spectrum disorder. Alternative splicing results in multiple variants. [provided by RefSeq, Jul 2017]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.